StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00. The firm has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- 5 Top Rated Dividend Stocks to Consider
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.